Finasteride for Chronic Central Serous Chorioretinopathy
| Autor: | Farzin Forooghian, Catherine B. Meyerle, Catherine A Cukras, Annal D. Meleth, Emily Y. Chew, Wai T. Wong |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Visual acuity genetic structures Hydrocortisone Urinary system Visual Acuity Pilot Projects Article chemistry.chemical_compound 5-alpha Reductase Inhibitors Ophthalmology medicine Humans Testosterone Prospective Studies Fluorescein Angiography Prospective cohort study medicine.diagnostic_test business.industry Finasteride Dihydrotestosterone General Medicine Middle Aged Fluorescein angiography Prognosis Discontinuation Surgery Serous fluid chemistry Central Serous Chorioretinopathy Chronic Disease medicine.symptom business Tomography Optical Coherence |
| Popis: | Purpose To evaluate the safety and efficacy of finasteride, an inhibitor of dihydrotestosterone synthesis, in the treatment of chronic central serous chorioretinopathy. Methods Five patients with chronic central serous chorioretinopathy were prospectively enrolled in this pilot study. Patients were administered finasteride (5 mg) daily for 3 months, after which study medication was withheld and patients were observed for 3 months. Main outcome measures included best-corrected visual acuity, central subfield macular thickness, and subretinal fluid volume as assessed by optical coherence tomography. Serum dihydrotestosterone, serum testosterone, and urinary cortisol were also measured. Results There was no change in mean best-corrected visual acuity. Mean center-subfield macular thickness and subretinal fluid volume reached a nadir at 3 months and rose to levels that were below baseline by 6 months. The changes in both optical coherence tomography parameters paralleled those in serum dihydrotestosterone level. In four patients, center-subfield macular thickness and/or subretinal fluid volume increased after discontinuation of finasteride. In the remaining patient, both optical coherence tomography parameters normalized with finasteride and remained stable when the study medication was discontinued. Conclusion Finasteride may represent a novel medical treatment for chronic central serous chorioretinopathy. Larger controlled clinical trials are needed to further assess the efficacy of finasteride for the treatment of central serous chorioretinopathy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|